ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Myelodysplastic Syndrome Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-3G3624
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Myelodysplastic Syndrome Market Insights and Forecast to 2028
BUY CHAPTERS

Global Myelodysplastic Syndrome Market Research Report 2025

Code: QYRE-Auto-3G3624
Report
September 2025
Pages:110
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli Lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
Sumitomo
GlaxoSmithKline
GlaxoSmithKline PLC
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals

Myelodysplastic Syndrome Market

The global market for Myelodysplastic Syndrome was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Myelodysplastic Syndrome is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Myelodysplastic Syndrome is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Myelodysplastic Syndrome in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Myelodysplastic Syndrome include Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Myelodysplastic Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myelodysplastic Syndrome.
The Myelodysplastic Syndrome market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Myelodysplastic Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myelodysplastic Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Myelodysplastic Syndrome Market Report

Report Metric Details
Report Name Myelodysplastic Syndrome Market
Segment by Type
  • Alkylating Agents
  • Cytotoxic Antibiotics
  • Topoisomerase Inhibitors
  • Others
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Astex, Celator Pharmaceuticals, Eli-lilly, Sunesis Pharmaceuticals, Targazyme, Gamida Cell, GlaxoSmithKline, Sumitomo Dainippon Pharma, TetraLogic Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Myelodysplastic Syndrome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Myelodysplastic Syndrome Market report?

Ans: The main players in the Myelodysplastic Syndrome Market are Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Onconova Therapeutics, Strategia Therapeutics, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Astex, Celator Pharmaceuticals, Eli-lilly, Sunesis Pharmaceuticals, Targazyme, Gamida Cell, GlaxoSmithKline, Sumitomo Dainippon Pharma, TetraLogic Pharmaceuticals

What are the Application segmentation covered in the Myelodysplastic Syndrome Market report?

Ans: The Applications covered in the Myelodysplastic Syndrome Market report are Hospital, Clinic

What are the Type segmentation covered in the Myelodysplastic Syndrome Market report?

Ans: The Types covered in the Myelodysplastic Syndrome Market report are Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Alkylating Agents
1.2.3 Cytotoxic Antibiotics
1.2.4 Topoisomerase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Market Perspective (2020-2031)
2.2 Global Myelodysplastic Syndrome Growth Trends by Region
2.2.1 Global Myelodysplastic Syndrome Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Myelodysplastic Syndrome Historic Market Size by Region (2020-2025)
2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Region (2026-2031)
2.3 Myelodysplastic Syndrome Market Dynamics
2.3.1 Myelodysplastic Syndrome Industry Trends
2.3.2 Myelodysplastic Syndrome Market Drivers
2.3.3 Myelodysplastic Syndrome Market Challenges
2.3.4 Myelodysplastic Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2020-2025)
3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2020-2025)
3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Myelodysplastic Syndrome Revenue
3.4 Global Myelodysplastic Syndrome Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2024
3.5 Global Key Players of Myelodysplastic Syndrome Head office and Area Served
3.6 Global Key Players of Myelodysplastic Syndrome, Product and Application
3.7 Global Key Players of Myelodysplastic Syndrome, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2020-2025)
4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2026-2031)
5 Myelodysplastic Syndrome Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2020-2025)
5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Myelodysplastic Syndrome Market Size (2020-2031)
6.2 North America Myelodysplastic Syndrome Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Myelodysplastic Syndrome Market Size by Country (2020-2025)
6.4 North America Myelodysplastic Syndrome Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome Market Size (2020-2031)
7.2 Europe Myelodysplastic Syndrome Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Myelodysplastic Syndrome Market Size by Country (2020-2025)
7.4 Europe Myelodysplastic Syndrome Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome Market Size (2020-2031)
8.2 Asia-Pacific Myelodysplastic Syndrome Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2020-2025)
8.4 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome Market Size (2020-2031)
9.2 Latin America Myelodysplastic Syndrome Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Myelodysplastic Syndrome Market Size by Country (2020-2025)
9.4 Latin America Myelodysplastic Syndrome Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome Market Size (2020-2031)
10.2 Middle East & Africa Myelodysplastic Syndrome Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2020-2025)
10.4 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.1.5 Celgene Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myelodysplastic Syndrome Introduction
11.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Details
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.3.5 Otsuka Recent Development
11.4 Actinium Pharmaceuticals
11.4.1 Actinium Pharmaceuticals Company Details
11.4.2 Actinium Pharmaceuticals Business Overview
11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction
11.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.4.5 Actinium Pharmaceuticals Recent Development
11.5 Acceleron Pharma
11.5.1 Acceleron Pharma Company Details
11.5.2 Acceleron Pharma Business Overview
11.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction
11.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.5.5 Acceleron Pharma Recent Development
11.6 Bellicum Pharmaceuticals
11.6.1 Bellicum Pharmaceuticals Company Details
11.6.2 Bellicum Pharmaceuticals Business Overview
11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction
11.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.6.5 Bellicum Pharmaceuticals Recent Development
11.7 Cornerstone Pharmaceuticals
11.7.1 Cornerstone Pharmaceuticals Company Details
11.7.2 Cornerstone Pharmaceuticals Business Overview
11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction
11.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.7.5 Cornerstone Pharmaceuticals Recent Development
11.8 CTI BioPharma
11.8.1 CTI BioPharma Company Details
11.8.2 CTI BioPharma Business Overview
11.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction
11.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.8.5 CTI BioPharma Recent Development
11.9 Onconova Therapeutics
11.9.1 Onconova Therapeutics Company Details
11.9.2 Onconova Therapeutics Business Overview
11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction
11.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.9.5 Onconova Therapeutics Recent Development
11.10 Strategia Therapeutics
11.10.1 Strategia Therapeutics Company Details
11.10.2 Strategia Therapeutics Business Overview
11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction
11.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.10.5 Strategia Therapeutics Recent Development
11.11 KaloBios Pharmaceuticals
11.11.1 KaloBios Pharmaceuticals Company Details
11.11.2 KaloBios Pharmaceuticals Business Overview
11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction
11.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.11.5 KaloBios Pharmaceuticals Recent Development
11.12 Kiadis Pharma
11.12.1 Kiadis Pharma Company Details
11.12.2 Kiadis Pharma Business Overview
11.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction
11.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.12.5 Kiadis Pharma Recent Development
11.13 Mirati Therapeutics
11.13.1 Mirati Therapeutics Company Details
11.13.2 Mirati Therapeutics Business Overview
11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction
11.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.13.5 Mirati Therapeutics Recent Development
11.14 Astex
11.14.1 Astex Company Details
11.14.2 Astex Business Overview
11.14.3 Astex Myelodysplastic Syndrome Introduction
11.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.14.5 Astex Recent Development
11.15 Celator Pharmaceuticals
11.15.1 Celator Pharmaceuticals Company Details
11.15.2 Celator Pharmaceuticals Business Overview
11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction
11.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.15.5 Celator Pharmaceuticals Recent Development
11.16 Eli-lilly
11.16.1 Eli-lilly Company Details
11.16.2 Eli-lilly Business Overview
11.16.3 Eli-lilly Myelodysplastic Syndrome Introduction
11.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.16.5 Eli-lilly Recent Development
11.17 Sunesis Pharmaceuticals
11.17.1 Sunesis Pharmaceuticals Company Details
11.17.2 Sunesis Pharmaceuticals Business Overview
11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction
11.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.17.5 Sunesis Pharmaceuticals Recent Development
11.18 Targazyme
11.18.1 Targazyme Company Details
11.18.2 Targazyme Business Overview
11.18.3 Targazyme Myelodysplastic Syndrome Introduction
11.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.18.5 Targazyme Recent Development
11.19 Gamida Cell
11.19.1 Gamida Cell Company Details
11.19.2 Gamida Cell Business Overview
11.19.3 Gamida Cell Myelodysplastic Syndrome Introduction
11.19.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.19.5 Gamida Cell Recent Development
11.20 GlaxoSmithKline
11.20.1 GlaxoSmithKline Company Details
11.20.2 GlaxoSmithKline Business Overview
11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction
11.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.20.5 GlaxoSmithKline Recent Development
11.21 Sumitomo Dainippon Pharma
11.21.1 Sumitomo Dainippon Pharma Company Details
11.21.2 Sumitomo Dainippon Pharma Business Overview
11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction
11.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.21.5 Sumitomo Dainippon Pharma Recent Development
11.22 TetraLogic Pharmaceuticals
11.22.1 TetraLogic Pharmaceuticals Company Details
11.22.2 TetraLogic Pharmaceuticals Business Overview
11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction
11.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025)
11.22.5 TetraLogic Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli Lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
Sumitomo
GlaxoSmithKline
GlaxoSmithKline PLC
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals
List of Tables
 Table 1. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Alkylating Agents
 Table 3. Key Players of Cytotoxic Antibiotics
 Table 4. Key Players of Topoisomerase Inhibitors
 Table 5. Key Players of Others
 Table 6. Global Myelodysplastic Syndrome Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Myelodysplastic Syndrome Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Myelodysplastic Syndrome Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Myelodysplastic Syndrome Market Share by Region (2020-2025)
 Table 10. Global Myelodysplastic Syndrome Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Myelodysplastic Syndrome Market Share by Region (2026-2031)
 Table 12. Myelodysplastic Syndrome Market Trends
 Table 13. Myelodysplastic Syndrome Market Drivers
 Table 14. Myelodysplastic Syndrome Market Challenges
 Table 15. Myelodysplastic Syndrome Market Restraints
 Table 16. Global Myelodysplastic Syndrome Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Myelodysplastic Syndrome Market Share by Players (2020-2025)
 Table 18. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2024)
 Table 19. Ranking of Global Top Myelodysplastic Syndrome Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Myelodysplastic Syndrome, Headquarters and Area Served
 Table 22. Global Key Players of Myelodysplastic Syndrome, Product and Application
 Table 23. Global Key Players of Myelodysplastic Syndrome, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Myelodysplastic Syndrome Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Myelodysplastic Syndrome Revenue Market Share by Type (2020-2025)
 Table 27. Global Myelodysplastic Syndrome Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Myelodysplastic Syndrome Revenue Market Share by Type (2026-2031)
 Table 29. Global Myelodysplastic Syndrome Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Myelodysplastic Syndrome Revenue Market Share by Application (2020-2025)
 Table 31. Global Myelodysplastic Syndrome Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Myelodysplastic Syndrome Revenue Market Share by Application (2026-2031)
 Table 33. North America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Myelodysplastic Syndrome Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Myelodysplastic Syndrome Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Myelodysplastic Syndrome Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Myelodysplastic Syndrome Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Myelodysplastic Syndrome Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Myelodysplastic Syndrome Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Myelodysplastic Syndrome Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Celgene Company Details
 Table 49. Celgene Business Overview
 Table 50. Celgene Myelodysplastic Syndrome Product
 Table 51. Celgene Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 52. Celgene Recent Development
 Table 53. Novartis Company Details
 Table 54. Novartis Business Overview
 Table 55. Novartis Myelodysplastic Syndrome Product
 Table 56. Novartis Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 57. Novartis Recent Development
 Table 58. Otsuka Company Details
 Table 59. Otsuka Business Overview
 Table 60. Otsuka Myelodysplastic Syndrome Product
 Table 61. Otsuka Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 62. Otsuka Recent Development
 Table 63. Actinium Pharmaceuticals Company Details
 Table 64. Actinium Pharmaceuticals Business Overview
 Table 65. Actinium Pharmaceuticals Myelodysplastic Syndrome Product
 Table 66. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 67. Actinium Pharmaceuticals Recent Development
 Table 68. Acceleron Pharma Company Details
 Table 69. Acceleron Pharma Business Overview
 Table 70. Acceleron Pharma Myelodysplastic Syndrome Product
 Table 71. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 72. Acceleron Pharma Recent Development
 Table 73. Bellicum Pharmaceuticals Company Details
 Table 74. Bellicum Pharmaceuticals Business Overview
 Table 75. Bellicum Pharmaceuticals Myelodysplastic Syndrome Product
 Table 76. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 77. Bellicum Pharmaceuticals Recent Development
 Table 78. Cornerstone Pharmaceuticals Company Details
 Table 79. Cornerstone Pharmaceuticals Business Overview
 Table 80. Cornerstone Pharmaceuticals Myelodysplastic Syndrome Product
 Table 81. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 82. Cornerstone Pharmaceuticals Recent Development
 Table 83. CTI BioPharma Company Details
 Table 84. CTI BioPharma Business Overview
 Table 85. CTI BioPharma Myelodysplastic Syndrome Product
 Table 86. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 87. CTI BioPharma Recent Development
 Table 88. Onconova Therapeutics Company Details
 Table 89. Onconova Therapeutics Business Overview
 Table 90. Onconova Therapeutics Myelodysplastic Syndrome Product
 Table 91. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 92. Onconova Therapeutics Recent Development
 Table 93. Strategia Therapeutics Company Details
 Table 94. Strategia Therapeutics Business Overview
 Table 95. Strategia Therapeutics Myelodysplastic Syndrome Product
 Table 96. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 97. Strategia Therapeutics Recent Development
 Table 98. KaloBios Pharmaceuticals Company Details
 Table 99. KaloBios Pharmaceuticals Business Overview
 Table 100. KaloBios Pharmaceuticals Myelodysplastic Syndrome Product
 Table 101. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 102. KaloBios Pharmaceuticals Recent Development
 Table 103. Kiadis Pharma Company Details
 Table 104. Kiadis Pharma Business Overview
 Table 105. Kiadis Pharma Myelodysplastic Syndrome Product
 Table 106. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 107. Kiadis Pharma Recent Development
 Table 108. Mirati Therapeutics Company Details
 Table 109. Mirati Therapeutics Business Overview
 Table 110. Mirati Therapeutics Myelodysplastic Syndrome Product
 Table 111. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 112. Mirati Therapeutics Recent Development
 Table 113. Astex Company Details
 Table 114. Astex Business Overview
 Table 115. Astex Myelodysplastic Syndrome Product
 Table 116. Astex Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 117. Astex Recent Development
 Table 118. Celator Pharmaceuticals Company Details
 Table 119. Celator Pharmaceuticals Business Overview
 Table 120. Celator Pharmaceuticals Myelodysplastic Syndrome Product
 Table 121. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 122. Celator Pharmaceuticals Recent Development
 Table 123. Eli-lilly Company Details
 Table 124. Eli-lilly Business Overview
 Table 125. Eli-lilly Myelodysplastic Syndrome Product
 Table 126. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 127. Eli-lilly Recent Development
 Table 128. Sunesis Pharmaceuticals Company Details
 Table 129. Sunesis Pharmaceuticals Business Overview
 Table 130. Sunesis Pharmaceuticals Myelodysplastic Syndrome Product
 Table 131. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 132. Sunesis Pharmaceuticals Recent Development
 Table 133. Targazyme Company Details
 Table 134. Targazyme Business Overview
 Table 135. Targazyme Myelodysplastic Syndrome Product
 Table 136. Targazyme Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 137. Targazyme Recent Development
 Table 138. Gamida Cell Company Details
 Table 139. Gamida Cell Business Overview
 Table 140. Gamida Cell Myelodysplastic Syndrome Product
 Table 141. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 142. Gamida Cell Recent Development
 Table 143. GlaxoSmithKline Company Details
 Table 144. GlaxoSmithKline Business Overview
 Table 145. GlaxoSmithKline Myelodysplastic Syndrome Product
 Table 146. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 147. GlaxoSmithKline Recent Development
 Table 148. Sumitomo Dainippon Pharma Company Details
 Table 149. Sumitomo Dainippon Pharma Business Overview
 Table 150. Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product
 Table 151. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 152. Sumitomo Dainippon Pharma Recent Development
 Table 153. TetraLogic Pharmaceuticals Company Details
 Table 154. TetraLogic Pharmaceuticals Business Overview
 Table 155. TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product
 Table 156. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2020-2025) & (US$ Million)
 Table 157. TetraLogic Pharmaceuticals Recent Development
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Myelodysplastic Syndrome Picture
 Figure 2. Global Myelodysplastic Syndrome Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Myelodysplastic Syndrome Market Share by Type: 2024 VS 2031
 Figure 4. Alkylating Agents Features
 Figure 5. Cytotoxic Antibiotics Features
 Figure 6. Topoisomerase Inhibitors Features
 Figure 7. Others Features
 Figure 8. Global Myelodysplastic Syndrome Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Myelodysplastic Syndrome Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Clinic Case Studies
 Figure 12. Myelodysplastic Syndrome Report Years Considered
 Figure 13. Global Myelodysplastic Syndrome Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Myelodysplastic Syndrome Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Myelodysplastic Syndrome Market Share by Region: 2024 VS 2031
 Figure 16. Global Myelodysplastic Syndrome Market Share by Players in 2024
 Figure 17. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2024
 Figure 19. North America Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Myelodysplastic Syndrome Market Share by Country (2020-2031)
 Figure 21. United States Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Myelodysplastic Syndrome Market Share by Country (2020-2031)
 Figure 25. Germany Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Myelodysplastic Syndrome Market Share by Region (2020-2031)
 Figure 33. China Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Myelodysplastic Syndrome Market Share by Country (2020-2031)
 Figure 41. Mexico Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Myelodysplastic Syndrome Market Share by Country (2020-2031)
 Figure 45. Turkey Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Myelodysplastic Syndrome Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Celgene Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 49. Novartis Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 50. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 51. Actinium Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 52. Acceleron Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 53. Bellicum Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 54. Cornerstone Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 55. CTI BioPharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 56. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 57. Strategia Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 58. KaloBios Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 59. Kiadis Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 60. Mirati Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 61. Astex Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 62. Celator Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 63. Eli-lilly Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 64. Sunesis Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 65. Targazyme Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 66. Gamida Cell Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 67. GlaxoSmithKline Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 68. Sumitomo Dainippon Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 69. TetraLogic Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2020-2025)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Molecular Diagnosis of Myelodysplastic Syndrome Market Research Report 2024
Global Myelodysplastic Syndrome Drug Market Research Report 2025
Global Myelodysplastic Syndrome Treatment Market Research Report 2024
Global Myelodysplastic Syndrome MDS Therapeutics Market Research Report 2024
Global Bone Marrow Collection System Market Research Report 2024
Acute Myeloid Leukemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Bone Marrow Product Market Research Report 2024
Global Bone Marrow Harvesting System Market Research Report 2024
Global Mesenchymal Stem Cell Medium Market Research Report 2025
Global Cord Blood Stem Cell Storage Service Market Research Report 2025
Global Stem Cell Storage Services Market Research Report 2024
Global Rare Hematology Market Research Report 2025
Global Stem Cell Source Market Research Report 2024
Global Granulocyte Colony Stimulating Factor G CSF Market Research Report 2024
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mesenchymal Stem Cell Media Market Research Report 2024
Global AML Screening Market Research Report 2024
Global Umbilical Cord Blood Hematopoietic Stem Cell Bank Market Research Report 2025
Bone Marrow Medium Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global LiHMDS Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions